Scarpignato, Carmelo http://orcid.org/0000-0001-5645-857X
Hunt, Richard H.
Funding for this research was provided by:
Università degli Studi di Parma
Article History
Accepted: 9 July 2024
First Online: 15 August 2024
Declarations
:
: Professor Scarpignato is member of the Advisory Board of Phathom and Professor Hunt is member of the Advisory Board of Cinclus. The first Company developed and is marketing a P-CAB (vonoprazan) in the US, while the second one is developing another P-CAB (namely Linaprazan glurate).